Strategic partnerships Aptar Digital Health is actively forming partnerships with pharma and tech firms, including Enable Injections, ŌURA, AstraZeneca, QoL Geneva, Biogen, and SHL Medical. Sales opportunity: position complementary digital health solutions and data analytics capabilities as value-adds to accelerate co-development, licensing, or integration deals with biopharma and medical device manufacturers.

Neurology and rare diseases The company has existing engagement in neurological and rare disease care through Biogen and migraine research collaborations, suggesting a market demand for digital health solutions in complex patient cohorts. Sales angle: tailor patient engagement platforms, remote monitoring, and data analytics for CNS and rare disease programs.

Migraine and patient experience Aptar Digital Health emphasizes improving patient journeys and has Migraine Buddy integration with ŌURA. Opportunity: offer end-to-end digital interventions, patient onboarding and analytics to pharmaceutical and healthcare providers focusing on migraine and other chronic conditions.

Digital health portfolio The business combines mobile and web apps, connected drug delivery, onboarding, training, and analytics within a holistic ecosystem. Sales tactic: propose bundled solutions to pharma partners seeking integrated digital health platforms that connect dosing devices with patient-facing software and data insights.

Global scaling and funding With a global leadership position in dosing and protection technologies under AptarGroup, plus $32M in funding and a revenue range of $1M-$10M, there is room to scale through strategic partnerships, platform licensing, and enterprise agreements. Sales strategy: pursue larger pharma and device manufacturers for scalable deployments and co-developed AI-enabled screening or care pathways.